Patterns of autoantibody expression in multiple sclerosis identified through development of an autoantigen discovery technology.

ABSTRACT: Multiple sclerosis (MS) is a debilitating autoimmune disease of the CNS, which is characterized by demyelination and axonal injury and frequently preceded by a demyelinating event called clinically isolated syndrome (CIS). Despite the importance of B cells and autoantibodies in MS pathology, their target specificities remain largely unknown. For an agnostic and comprehensive evaluation of autoantibodies in MS, we developed and employed what we believe to be a novel autoantigen discovery technology, the Antigenome Platform. This Platform is a high-throughput assay comprising large-fragment (approximately 100 amino acids) cDNA libraries, phage display, serum antibody screening technology, and robust bioinformatics analysis pipelines. For autoantibody discovery, we assayed serum samples from

SUBMITTER: DiCillo EB 

PROVIDER: S-EPMC11870742 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature